This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Skeletal muscle possesses remarkable regeneration potential, which largely is attributable to satellite cells and other muscle stem cells that reside in adult muscle. Satellite cells, therefore, are of great interest for therapeutic applications for muscle injury and degenerative diseases. To develop effective therapeutics based on satellite cell biology, it is critical to identify key signaling factors, pathways, and mechanisms that regulate their proliferation and/or differentiation during muscle repair and regeneration. R-spondins are a novel class of secreted proteins that activate Wnt/beta-catenin pathways. The PI's laboratory has discovered R-spondin2 expression is markedly and selectively increased during muscle regeneration, with close overlapping timing with satellite cell proliferation and myogenic differentiation. This suggests that R-spondin2 may selectively promote proliferation and/or differentiation of skeletal muscle satellite cells via Wnt signaling pathways. Using in vitro primary cell culture and in vivo mouse models, we will 1) determine the roles of R-spondin2 in promoting proliferation and/or myogenic differentiation of satellite cells, and define key R-spondin2 signaling pathways;and 2) determine how gain or loss of R-spondin2 function affects skeletal muscle regeneration in vivo.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR018789-08
Application #
8167683
Study Section
Special Emphasis Panel (ZRR1-RI-6 (01))
Project Start
2010-06-01
Project End
2011-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
8
Fiscal Year
2010
Total Cost
$226,071
Indirect Cost
Name
Maine Medical Center
Department
Type
DUNS #
071732663
City
Portland
State
ME
Country
United States
Zip Code
04102
Duarte, Christine W; Black, Adam W; Lucas, F Lee et al. (2017) Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol 143:209-214
Caron, Jennifer M; Ames, Jacquelyn J; Contois, Liangru et al. (2016) Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope. Am J Pathol 186:1649-61
Stohn, J Patrizia; Wang, Qiaozeng; Siviski, Matthew E et al. (2015) Cthrc1 controls adipose tissue formation, body composition, and physical activity. Obesity (Silver Spring) 23:1633-42
Ufkin, Melanie L; Peterson, Sarah; Yang, Xuehui et al. (2014) miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 38:402-10
He, Qing; Yang, Xuehui; Gong, Yan et al. (2014) Deficiency of Sef is associated with increased postnatal cortical bone mass by regulating Runx2 activity. J Bone Miner Res 29:1217-31
Motyl, Katherine J; Bishop, Kathleen A; DeMambro, Victoria E et al. (2013) Altered thermogenesis and impaired bone remodeling in Misty mice. J Bone Miner Res 28:1885-97
Urs, Sumithra; Henderson, Terry; Le, Phuong et al. (2012) Tissue-specific expression of Sprouty1 in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction. Br J Nutr 108:1025-33
Sathyanarayana, Pradeep; Dev, Arvind; Pradeep, Anamika et al. (2012) Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood 119:5522-31
Motyl, Katherine J; Dick-de-Paula, Ingrid; Maloney, Ann E et al. (2012) Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 50:490-8
Favreau, Amanda J; Cross, Erin L; Sathyanarayana, Pradeep (2012) miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. Am J Hematol 87:442-6

Showing the most recent 10 out of 102 publications